R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis

Yuna Guo1,2, S. Ray Kenney2,3, Carolyn Y. Muller2,4, Sarah Adams2,4, Teresa Rutledge2,4, Elsa Romero1, Cristina Murray-Krezan5, Rytis Prekeris6, Larry A. Sklar1,2, Laurie G. Hudson2,3, and Angela Wandinger-Ness1,2

Abstract

Cdc42 (cell division control protein 42) and Rac1 (Ras-related C3 botulinum toxin substrate 1) are attractive therapeutic targets in ovarian cancer based on established importance in tumor cell migration, adhesion, and invasion. Despite a predicted benefit, targeting GTPases has not yet been translated to clinical practice. We previously established that Cdc42 and constitutively active Rac1 are overexpressed in primary ovarian tumor tissues. Through high-throughput screening and computational shape homology approaches, we identified R-ketorolac as a Cdc42 and Rac1 inhibitor, distinct from the anti-inflammatory, cyclooxygenase inhibitory activity of S-ketorolac. In the present study, we establish R-ketorolac as an allosteric inhibitor of Cdc42 and Rac1. Cell-based assays validate R-ketorolac activity against Cdc42 and Rac1. Studies on immortalized human ovarian adenocarcinoma cells (SKOV3ip) and primary patient-derived ovarian cancer cells show that R-ketorolac is a robust inhibitor of growth factor or serum-dependent Cdc42 and Rac1 activation with a potency and cellular efficacy similar to small-molecule inhibitors of Cdc42 (CID2950007/ML141) and Rac1 (NSC23766). Furthermore, GTPase inhibition by R-ketorolac reduces downstream p21-activated kinases (PAK1/PAK2) effector activation by >80%. Multiple assays of cell behavior using SKOV3ip and primary patient-derived ovarian cancer cells show that R-ketorolac significantly inhibits cell adhesion, migration, and invasion. In summary, we provide evidence for R-ketorolac as a direct inhibitor of Cdc42 and Rac1 that is capable of modulating downstream GTPase-dependent, physiologic responses, which are critical to tumor metastasis. Our findings demonstrate the selective inhibition of Cdc42 and Rac1 GTPases by an FDA-approved drug, racemic ketorolac, that can be used in humans. Mol Cancer Ther; 14(10); 2215–27. ©2015 AACR.

Introduction

Ovarian cancer is the leading cause of gynecologic cancer deaths in the United States with a 45% 5-year survival rate (1). Often associated with malignant ascites, which facilitates metastasis, most patients are diagnosed at advanced stages with dissemination throughout the intraperitoneal cavity (2). Recent understanding of the etiology of ovarian cancer suggests that the majority of serous ovarian cancers originate from dysplastic fallopian tubes (3). Metastatic spread of ovarian cancer beyond the ovary or fallopian tube is mediated by surface shedding of tumor cells and formation of free-floating multicellular aggregates in the ascites fluid. Subsequent mesothelial anchoring and invasion of the submesothelial matrix leads to secondary lesions on peritoneal organs and surfaces (4). Consequently, the first line of treatment involves major debulking surgery to remove as much tumor burden as possible, most often followed by intraperitoneal chemotherapy treatment in optimally debulked patients after recovery from surgery. Therefore, targeting tumor cell adhesion, migration, and invasion in the perioperative period, during which tumor dissemination may occur and impact ovarian cancer recurrence, presents an important potential window of opportunity for treatment that has not yet been extensively explored (5, 6).

It is well established that Rho family (Ras homolog) GTPases are central to dynamic actin cytoskeletal assembly and rearrangement that are the underpinnings of normal cell–cell adhesion, cell migration, and even transformation (7). Among the Rho family GTPases, Cdc42 (cell division control protein 42) and Rac1 (Ras-related C3 botulinum toxin substrate 1) are of particular interest on account of their frequent overexpression or hyperactivation in epithelial cancers, including ovarian cancer (8–12). In response to extracellular stimuli, Cdc42 and Rac1 GTPase transition from an inactive GDP-bound status to an active GTP-bound status and interact with downstream effectors to propagate changes in cell behaviors (7). For example, activated Cdc42 and Rac1 phosphorylate p21-activated kinases (PAK1/PAK2) which in turn initiate
cells were obtained from nine patients from 2012 to 2015. SKO-
(Houston, TX) in June 24, 2009. The ascites derived ovarian cancer
metastatic phenotype in the mice and was obtained under a
V3ip was derived from SKOV3 cell line by selecting for a peritoneal
Cell and reagents
Materials and Methods
actin reorganization and subsequently regulate cell adhesion,
migration, and invasion (13). Furthermore, the Rac1–PAK sig-
naling axis lies immediately downstream of growth factor activ-
ated Ras signaling and in ovarian cancer has been shown to
modulate epithelial-to-mesenchymal transition (EMT) and
angiogenesis (14, 15). Therefore, it is of interest to investigate
the utility of Cdc42 and Rac1 as points of intervention in the
intraperitoneal spread of ovarian cancer.

While Cdc42 and Rac1 are potential high value, therapeutic
targets in ovarian and other cancers, key gaps remain in translating
known GTPase inhibitors into clinical application. Statins are
HMG-CoA reductase inhibitors that indirectly act as broad spec-
trum GTPase inhibitors by interfering with the prenylation
required for functionally essential membrane association (16).
Cancer risk reductions associated with statin use are reported for
breast, colorectal, and pancreatic cancers (17–19). The benefit in
ovarian cancer is mixed and subtype specific (20), motivating the
identification and testing of more selective GTPase inhibitors.
Several GTPase-targeted inhibitors have been identified with various modes of action. Yet, irrespective of whether they affect
signaling (e.g., NSC23766, secramine; refs. 21, 22), nucleotide-
binding ability (e.g., CID2950007 (PubChem compound iden-
tification for Cdc42 GTPase inhibitor); ref. 23), or effector-bind-
ing activity (e.g., Y27632; ref. 24), none have as yet been translated
to human use.

Using a combination of high-throughput screening and
computational simulation, the R-enantiomer of ketorolac was
identified as a selective Cdc42 and Rac1 inhibitor, without effect
on RhoA (25). Kitorolac is clinically administered as a racemic
mixture for pain relief, based on the activity of S-ketorolac as a
dual (COX1/COX2) inhibitor (26, 27, 28). The R-enantiomer
was considered inert prior to our identification of its Cdc42 and Rac1
inhibitory activity (25). Published literature on breast, lung, and
kidney cancer patients and our own data on ovarian cancer
patients demonstrates that besides its analgesic function, ketor-
olac has significant benefit for patient survival (6, 12, 29, 30).
The mechanism of this anticancer action is not clear, yet appears to be
selectively ascribed to ketorolac and not a general property of
cyclooxygenase inhibitors or other analgesics and anesthetics
(6, 31, 32). This suggests that ketorolac possesses an additional
property. In the current study, a human patient immortalized
ovarian cancer cell line (SKOV3ip) and primary ascites-derived
ovarian cancer cells were used to demonstrate that R-ketorolac acts
as an allosteric inhibitor of Cdc42 and Rac1 nucleotide binding
activities in vitro and blocks their activation and downstream
activation of the PAK signaling axis. As a consequence of the
inhibition, there is a reduction in ovarian cancer cell adhesion,
migration, and invasion. Taken together, the data demonstrate the
potential for repurposing R-ketorolac, an FDA-approved drug in
the racemic form, for improved patient benefit in progression-free
and overall survival.

Materials and Methods

Cell and reagents
The human ovarian adenocarcinoma epithelial cell line SKO-
V3ip was derived from SKOV3 cell line by selecting for a peritoneal
metastatic phenotype in the mice and was obtained under a
Material Transfer Agreement with MD Anderson Cancer Center
(Houston, TX) in June 24, 2009. The ascites derived ovarian cancer
cells were obtained from nine patients from 2012 to 2015. SKO-
V3ip cell line was authenticated using short tandem repeat analysis
(performed by Promega). SKOV3ip cells and primary ovarian
cancer cells were cultured in RPMI1640 media containing 5% FBS
(Atlanta Biologicals). All cell culture media and reagents were
purchased from Gibco (Life Technologies). R- and S-ketorolac were
from Toronto Research Chemical Inc. BODIPY-GTP [(4,4-difluoro-
4-bora-3a,4a-diaza-s-indacene or dipyrromethene boron difluor-
ide) nucleotide analogue] was from Invitrogen Molecular Probes.

Published OnlineFirst July 23, 2015; DOI: 10.1158/1535-7163.MCT-15-0419
Published OnlineFirst July 23, 2015; DOI: 10.1158/1535-7163.MCT-15-0419
Published OnlineFirst July 23, 2015; DOI: 10.1158/1535-7163.MCT-15-0419
enriched ovarian cancer cells were cultured on collagen-coated (20 μg/cm²) tissue culture dishes. After 3 to 4 days, when most of the tumor cells had adhered, the media were replaced and continued to be changed every 2 to 3 days until cells grew to confluence. The expanded cells were used for filopodia formation, cell adhesion, migration, and extracellular matrix degradation assays.

Synthesis of GSH beads for flow cytometry assay
High-density GSH-conjugated beads were synthesized for flow cytometry assays by loading Superdex peptide beads with GSH as previously reported (37).

Flow cytometric BODIPY-GTP–binding assay
The assay was carried out according to the protocols described previously (37). Briefly, individual GST-GTPases were attached to their respective GSH beads and combined. In the equilibrium assay, 2 × 10⁷ GSH beads loaded with GST-GTPase were pre-incubated with either dimethyl sulfoxide (DMSO) or a fixed concentration of BODIPY-GTP for 30 minutes at room temperature. For measurement, samples were diluted at least 10-fold and delivered and analyzed by the BD FACScan flow cytometer.

Flow cytometric GTPase effector–binding assay for quantification of active, cellular GTPase levels
The assay was carried out according to the protocols described previously (38). Ketorolac-treated and vehicle control cells were lysed in RIPA (high stringency cell lysis buffer) buffer (50 mmol/L Tris–HCl, 150 mmol/L NaCl, 1 mmol/L EDTA, 0.25% (w/v) Na-deoxycholate, 1 mmol/L Na₂VO₄, 1 mmol/L NaF, 1% (v/v) NP-40 (nonyl phenoxypolyethoxylethanol), 1 mmol/L phenylmethyl-sulfonyl fluoride and protease inhibitors consisting 10 μg/mL each of chymostatin, leupeptin, pepstatin, and antipain). Insoluble debris was removed by centrifugation, and the supernatants were incubated with GTPase effector-coated beads (PAK1-PBD for Cdc42 and Rac1) for 1 hour. Primary antibodies directed against Cdc42 or Rac1 and secondary antibody Alexa 488 (PAK1-PBD for Cdc42 and Rac1) for 1 hour. Primary antibodies were detected with specific antibodies directed against PAK and phosphor-PAK.

Quantification of filopodia formation
The assay was conducted as described previously (23). Cells were cultured on coverslips to 50% confluence and serum-starved for 2 hours, treated with individual drugs and stimulated with 10 ng/mL EGF for 20 minutes. Cells were gently rinsed three times with ice-cold PBS and fixed with 3% paraformaldehyde. Rhodamine phalloidin was used to label the actin. Images were collected using a Zeiss laser scanning microscope (LSM) 510 confocal microscope equipped with a 63× oil immersion lens. For each experiment, a战胜 pattern was used to select 30 images at random. Length and number of filopodia per cell were quantified using Slidebook 5.5 software.

Cell adhesion assay
The adhesion assay was modified from the method described by M.J. Humphrie (39). Cells were cultured at least for 48 hours and dissociated with 0.05% trypsin/EDTA. Suspended cells were rested in 0% FBS media for 1 hour and treated with individual drugs. Cells stimulated with 5% serum were seeded on a 96-well plate (5 × 10⁴ cells/well) coated with 0.5 μg/cm² fibronectin or collagen and permitted to attach for 1 hour. The 96-well plate was gently washed with PBS and cells were fixed with 3% paraformaldehyde. Samples were stained with crystal violet and lysed with 10% acetic acid and absorbance (λ = 595 nm) quantified using a plate reader.

Cell migration assay
SKOV3ip cells were plated at 1 × 10⁵ cells/well in 24-well Boyden chambers and allowed to attach for 4 hours. Ketorolac enantiomers were added to growth media at final concentrations ranging from 1 to 300 μmol/L. After 48 hours, inserts were removed and stained with 1% 6-diamidino-2-phenylindole. Membrane filters were imaged on a Zeiss inverted microscope using a 20× objective. Three representative fields were counted from each treatment group.

Gelatin degradation assay
The commercial gelatin degradation kit (Millipore) was used per the manufacturer’s instructions and modified to incorporate drug treatment and EFG stimulation as follows. Fluorescent gelatin was coated on coverslips as described previously (25). Cells were seeded on fluorescent coverslip and allowed to adhere for 6 hours and then treated with individual drugs for 24 hours. Cells were fixed with 3% paraformaldehyde, permeabilized with 0.1% Triton X-100, and immunostained for Tks5. Actin was visualized with FITC-phalloidin. Fifteen fields per coverslip were imaged on a Zeiss LSM 510 META with a 63× oil immersion objective. Gelatin degradation by invadopodia was analyzed using Slidebook 5.5 software. Percent degradation was quantified as: (degradation area)/(total cell area) for each image.

Western blot analysis
SKOV3ip cells were serum-starved for 2 hours and treated with individual drugs for 1 hour. After stimulation with 10 ng/mL EGF for 20 minutes, cells were washed with ice-cold PBS and lysed with RIPA buffer. Cell lysates were processed for SDS-PAGE, transferred to polyvinylidene fluoride membranes, and individual proteins were detected with specific antibodies directed against PAK and phosphor-PAK.

Statistical analyses
Prism 5 software (GraphPad) was used to analyze all data to determine statistical significance. One-way ANOVA with the Dunnett test for multiple comparisons was performed to compare differences between the means of each group relative to the control group for all assays. P values less than 0.05 were considered statistically significant. For some assays conducted on primary ovarian patient samples (GTPase activity measurements and gelatin degradation assays), standard z-scores of the values were calculated for each patient to minimize large ranges of values and...
to compare across groups on a uniform scale. ANOVA was performed on these standardized values.

**Results**

**R-ketorolac acts as an allosteric inhibitor of guanine nucleotide binding to Cdc42 and Rac1**

The enantiomeric selectivity of ketorolac (Fig. 1A) against Cdc42 and Rac1 was predicted by virtual screening and modeled in docking studies (25). To verify ketorolac inhibition of nucleotide binding activity and determine the mechanism of inhibition, a bead-based flow cytometry assay, which measures the in vitro GTPase nucleotide binding activity, was used. First, equilibrium nucleotide binding assays were performed under conditions where the tested compound concentration was held fixed against increasing concentrations of fluorescent nucleotide. In the presence of R-ketorolac, both the maximum fluorescence (B\text{max}) and the apparent dissociation constant (Kd) of BODIPY-GTP for Cdc42 and Rac1 changed, which suggests a noncompetitive mechanism of action (Fig. 1B and D and Supplementary Table S2). S-ketorolac did not change the B\text{max} and the Kd for Cdc42 (Fig. 1C and Supplementary Table S2) and exhibited a minor inhibition of Rac1 only at the maximum concentration of 100 μmol/L (Fig. 1E). Single-plex dose–response measurements were used to verify the enantiomer selectivity of ketorolac for inhibiting nucleotide binding by Cdc42 and Rac1. The nucleotide concentrations in the assay were fixed at the determined dissociation constants (Kd ≈ 300 nmol/L). Increasing R-ketorolac concentrations reduced BODIPY-GTP binding, with respective EC\text{50} (half-maximal effective concentration) values of 1.887 × 10^{-3} for Cdc42 and 2.308 × 10^{-3} for Rac1 (Fig. 1F and G). The maximal inhibitory response was approximately 20% for both GTPases. S-ketorolac did not exhibit an inhibitory activity against either GTPase under the tested conditions. Together, these findings suggest an enantiomer-selective, inhibitory activity of R-ketorolac against the nucleotide binding activity of Cdc42 and Rac1. Mechanistically, R-ketorolac action is consistent with an allosteric inhibition of GTPase nucleotide binding.

**R-ketorolac inhibits Cdc42 and Rac1 activation in immortalized and primary human ovarian cancer cells**

We have developed a flow cytometry–based assay for quantitatively assessing the levels of active GTPases in cell lysates (38). The assay was used to test the cellular impact of ketorolac isoforms on GTPase activation. Maximal Cdc42 and Rac1 activation in SKOV3ip cells treated with 10 ng/mL EGF occurred at different times; 20 minutes for Cdc42 and 5 minutes for Rac1 (Supplementary Fig. S1). Growth factor–stimulated activation of Cdc42 and Rac1 was differentially inhibited in an enantiomer-selective manner (Fig. 2A and B). R-ketorolac substantially inhibited growth factor–dependent activation of Cdc42 and Rac1 in a dose-dependent manner with an EC\text{50} value of 2.577 μmol/L for Cdc42 and 0.587 μmol/L for Rac1 (Fig. 2A and B, circles). In contrast, even at the highest dose of 100 μmol/L, S-ketorolac exhibited limited inhibition (less than 30% of maximum by R-ketorolac) of Cdc42 and Rac1 (Fig. 2A and B, squares). Enantiomer-selective inhibition was also found in HeLa cells treated with R-ketorolac (25). Control cytotoxicity measurements in different cell lines (SKOV3ip, OVCA 429, and OVCA 433) showed <10% inhibition of cell proliferation induced by either enantiomer of ketorolac at the highest tested dose and treatment time (300 μmol/L for 96 hours).

The effect of ketorolac was also examined in primary ovarian cancer cells purified from patient ascites. Surgery samples were obtained and analyzed as part of an approved clinical study (see Materials and Methods and Supplementary Table S1). Primary human ovarian cancer cells were enriched via Ficoll gradient centrifugation and depletion of lymphocytes using CD45 Dynabeads. Purified primary human ovarian cancer cells were positive for CA125 and EpCAM, which are commonly overexpressed in epithelial ovarian carcinomas (Supplementary Fig. S2; refs. 40, 41). Isolated tumor cells were treated with individual ketorolac isoforms or specific Cdc42 and Rac1 inhibitors and the endogenous Cdc42 and Rac1 activities were tested. Because of the heterogeneity in activity levels of the GTPases for individual patient samples, z-scores were used to comparatively evaluate the impact of ketorolac on tumor cell GTPase activities from different patients. Treatment with 10 μmol/L R-ketorolac reproducibly inhibited both Cdc42 and Rac1 in a statistically significant manner. The magnitude of R-ketorolac inhibition of Cdc42 or Rac1 was similar to the inhibition observed in positive controls treated with CID2950007, an allosteric Cdc42 inhibitor, or NSC23766, a Rac1 inhibitor that interferes with guanine nucleotide exchange factor (GEF)-mediated GTPase activation (21, 23). S-ketorolac exhibited limited inhibition and was not statistically significant (Fig. 2C and D). Taken together, the results demonstrate that R-ketorolac is a potent, enantiomer-selective inhibitor of Cdc42 and Rac1 in primary human ovarian cancer cells.

**Inhibition of Cdc42 and Rac1 by R-ketorolac decreases activation of downstream p21 activated kinases (PAK1/PAK2)**

The impact of R-ketorolac on PAK1/PAK2 effector signaling directly downstream of the Cdc42 and Rac1 GTPases was examined (Supplementary Fig. S3A). Cells stimulated with 10 ng/mL EGF exhibited robust phosphorylation of the Ser144/141 residues compared with unstimulated control cells. In contrast, there was a dose-dependent suppression of p-PAK1/PAK2 following R-ketorolac treatment that was similar to positive controls treated with Cdc42 or Rac1-specific inhibitors. S-ketorolac on the other hand had limited effect on p-PAK1/PAK2 levels at either 1 μmol/L or 10 μmol/L (Fig. 3A–C). The expression of total PAK1 was not affected by either R- or S-ketorolac treatment (Fig. 3A). These results demonstrate the suppression of p-PAK1/PAK2 activity paralleled the inhibition of Cdc42 and Rac1 in a dose-dependent manner following R-ketorolac treatment; and S-ketorolac exhibited no significant inhibition of p-PAK1/PAK2.

Phosphorylation of PAK1/PAK2 on two further residues (Thr423/402 or Ser199/204/Ser192/197) that are downstream of other signaling pathways were also examined. Interestingly, p-PAK1(Thr423)/PAK2(Thr402) and p-PAK1(Ser199/204)/PAK2(Ser192/197) were reduced by both Cdc42 or Rac1 inhibitors with greater variability and less pronounced enantiomeric selectivity (Supplementary Fig. S3A–S3E). For example, R-ketorolac consistently inhibited the phosphorylation at pPAK1/PAK2 (Thr423) with statistical significance at 1 μmol/L though more variably at 10 μmol/L. S-ketorolac exhibited statistically significant inhibitory effects at 10 μmol/L against Thr423/402, but not against Ser199/204/Ser192/197. Inhibition of phosphorylation by the Rac1 inhibitor NSC23766 and the Cdc42 inhibitor CID2950007 was
also more modest and failed to reach statistical significance in some instances. The explanation for the differences in responsiveness of individual phosphorylation sites is likely due to the fact that Ser144/141 is localized in an N-terminal regulatory domain and directly interacts with Cdc42 and Rac1 (Supplementary Fig. S3A). While Thr423/402 residues in the catalytic kinase

Figure 1.
R-ketorolac selectively inhibits Cdc42 and Rac1 GTPase BODIPY-GTP binding as an allosteric inhibitor. A, chemical structure of R- and S-ketorolac with chiral center noted. B and C, the presence of R-ketorolac changed both the $B_{\text{max}}$ and the $K_d$ (values are tabulated in Supplementary Table S2) of BODIPY-GTP binding to Cdc42 measured under equilibrium binding conditions, while S-ketorolac did not affect BODIPY-GTP binding. D and E, R-ketorolac changed the $B_{\text{max}}$ and the $K_d$ of BODIPY-GTP binding to Rac1 measured under equilibrium binding conditions, while S-ketorolac did not affect BODIPY-GTP binding except at 100 μmol/L. The equilibrium binding of BODIPY-GTP to the GTPases was measured in the presence of 0.1% DMSO or various concentrations of R- or S-ketorolac (1–100 μmol/L). BODIPY-GTP binding curves were fitted to a hyperbolic one-site binding equation from GraphPad Prism 5. F and G, R-ketorolac in contrast to S-ketorolac inhibited BODIPY-GTP binding to Cdc42 and Rac1 GTPases in a dose-dependent manner. BODIPY-GTP concentration was fixed at 300 nmol/L for these experiments. The inhibition curves were fitted to the sigmoidal dose-response equation from GraphPad Prism5. In all experiments, GST-Cdc42 or Rac1 were immobilized on GSH beads and used to measure BODIPY-GTP binding. Bead-associated fluorescence intensity was quantified by flow cytometry and used to monitor drug treatment-induced changes in nucleotide binding. All experiments were repeated three times independently.
domain and Ser199/204/Ser192/197 adjacent to autoinhibitory domain are targeted by other regulatory molecules in a GTPase-independent manner (42, 43). For example, S-ketorolac may inhibit phosphorylation on these sites by affecting lipid-dependent stimulation of PAK1/PAK2 (e.g., sphingosine) or through crosstalk between COX1/COX2 and PI3K signaling and the GTPase-PAK1/PAK2 pathway (44, 45).

**R-ketorolac inhibits Cdc42-dependent filopodia formation in SKOV3ip cells and primary ovarian cancer cells**

Filopodia are membrane protrusions that are constructed of bundled actin filaments and directly regulated by Cdc42 (46). The process of cell-substrate adhesion plays critical roles during cancer metastasis which is required for the anchoring of malignant spheroids to new sites (47). R-ketorolac preferentially inhibits Cdc42 and Rac1 activities in SKOV3ip cells and primary human ovarian cancer cells. A and B, R-ketorolac causes a dose-dependent, enantiomer-selective inhibition of Cdc42 and Rac1 activation in SKOV3ip cells. SKOV3ip cells were starved in 0% FBS media for 2 hours and pretreated with individual drugs for 2 hours prior to EGF (10 ng/mL) stimulation. Activated Cdc42 and Rac1 levels in cell lysates were measured using a flow cytometry-based GTPase effector binding assay. Fluorescence intensities were normalized to untreated controls. All experiments were repeated three times independently. C and D, R-ketorolac causes a dose-dependent, enantiomer-selective inhibition of endogenous Cdc42 and Rac1 activities in primary ovarian cancer cells. Isolated primary ovarian cancer cells from three independent patients were treated with drugs for 1 hour and processed for GTPase effector-binding assays to measure the GTPase activity. Six patient samples were tested for Cdc42 activity and five patient samples were tested for Rac1 activity in response (Supplementary Table S1). CID2950007 and NSC23766 served as Cdc42- and Rac1-specific inhibitors, respectively. Plotted are z-scores. Quantification of three independent measurements are plotted ±SEM. Statistically significant differences are indicated: *, P < 0.05; **, P < 0.01; ***, P < 0.001.
the extracellular matrix of target abdominal organs (4). A cell attachment assay was used to test the effect of ketorolac on cell adhesion. Stimulated cells were allowed to adhere to matrix-coated substrates. R-ketorolac reduced SKOV3ip cells adherence to both fibronectin and collagen and S-ketorolac had no significant effect (Fig. 5A and B). R-ketorolac also inhibited human primary ovarian cancer cell adhesion to collagen, while S-ketorolac had no significant effect (Fig. 5C). This observation suggests that the R-enantiomer of ketorolac inhibits cell-substrate adhesion likely as a biologic consequence of its inhibitory effect on upstream Cdc42 and Rac1 activation.

Cell migration. Activated by extracellular stimuli and dependent on GTPase activation, cell migration is initiated by the formation of membrane protrusions, including Cdc42-dependent filopodia and Rac1-mediated lamellipodia (7). SKOV3ip cell migration in the presence of R- or S-ketorolac was tested in a Boyden chamber assay. Migration was inhibited in a dose-dependent manner with R-ketorolac beginning to impinge on cell migration at 1 μmol/L. The inhibitory effect increased in a dose-dependent manner with maximum inhibition of approximately 80% at 300 μmol/L R-ketorolac (Fig. 5D). Modest inhibition by S-ketorolac was detected at about 50 μmol/L with a maximum inhibition less than 50% at 300 μmol/L. The results demonstrate that cell migration was inhibited as a direct biological consequence mediated by Cdc42 and Rac1 inhibition by R-ketorolac, whereas S-ketorolac was 50-fold less potent.

Invasion. Invadopodia are membrane protrusions that are dependent on activated Cdc42 and Src kinase. Invadopodia concentrate matrix metalloproteinases at their tips and based on their matrix degradative properties serve as surrogates for cell invasive behaviors (48). To study the effect of ketorolac on invadopodia formation, the invadopodia-dependent degradation of gelatin matrices was quantified. In Skov3ip cells, invadopodia were observed as puncta of F-actin and Tks5-positive structures, which colocalized with the degradation sites on the gelatin matrix (Fig. 6A). R-ketorolac treatment also resulted in reduced gelatin degradation in a dose-dependent manner with 70% to 80% inhibition at 1 and 10 μmol/L. However, S-ketorolac did not exert any obvious inhibition of gelatin degradation at 1 μmol/L and the reduction of gelatin degradation with 10 μmol/L S-ketorolac treatment was approximately 50% but failed to reach the statistical significance (Fig. 6B and D). Tks5 is an early marker of
invadopodia formation that precedes matrix metalloprotease localization to the tips of mature structures. To distinguish whether R-ketorolac had a direct inhibitory effect on metalloprotease activity or whether the observed effect on gelatin degradation was primarily due to inhibition of invadopodia formation, the impact on metalloproteinase activity secreted into the culture medium was also measured and found to be similar ± ketorolac. Therefore, we conclude that the primary effect of R-ketorolac is to prevent Cdc42-dependent invadopodia formation. When the gelatin degradation assay was conducted in primary ovarian cancer cells, the standardized z-scores showed the degradation of matrix by tumor cells was also significantly decreased in a dose-dependent manner by R-ketorolac treatment, while the inhibition by S-ketorolac was less and reached significance only at the highest dose (Fig. 6C and E). Z-scores were used to account for differences in absolute GTPase activity levels observed for individual patient samples (Fig. 2C and D), likely related to known differences in GTPase overexpression seen in ovarian cancer (11, 12). The inhibitory effect of R-ketorolac in primary ovarian cancer cells is consistent with the observations in SKOV3ip cells.

**Discussion**

In the current study, we establish R-ketorolac as an allosteric, noncompetitive inhibitor of guanine nucleotide binding to Cdc42 and Rac1. In its clinical application, ketorolac is given for its potent analgesic activity. It is administered as a racemic mixture via diverse routes (intravenous, injectable, oral, intranasal) and is known as Toradol. The pain relieving activity is ascribed primarily to its potent analgesic activity. It is administered as a racemic mixture of prostaglandin synthesis, and decreased immune suppression as compared with opioids and other analgesics (51), there was previously no precedence for other pharmacologic activities associated with R- or S-ketorolac. We speculate that the slight inhibitory effects of S-ketorolac on GTPase activation and actin-dependent cell behaviors may arise from crosstalk between COX2 and PI3K and integrin-regulated pathways. COX2-dependent crosstalk has been shown through knockout and pharmacologic means to regulate Cdc42 and Rac1 activation, and adhesion and migration of macrophages and endothelia (45, 52). Because R-ketorolac is a much less potent COX inhibitor than S-ketorolac, its more pronounced effect on GTPase activation and downstream cell behaviors indicates that it is primarily targeting Cdc42 and Rac1 through a direct mechanism. Furthermore, pharmacokinetic analyses show that S-ketorolac is more rapidly excreted, leading to an

---

**Figure 4.** R-ketorolac decreases Cdc42-dependent filopodia formation in SKOV3ip cells and primary human ovarian cancer cells following EGF stimulation. A, representative confocal images of filopodia formation for each treatment group in SKOV3ip cells are shown. Bottom panels are magnified images of the boxed regions. B and C, quantification of numbers and length of filopodia on each cell. D, representative confocal images of filopodia formation for each treatment group of primary human ovarian cancer cells are shown. Bottom panels are magnified images of the boxed regions. E and F, quantification of numbers and length of filopodia per cell in primary human ovarian cancer cells. For all experiments, cells were plated on coverslips and cultured overnight, then starved in 0% FBS media for 2 hours and pretreated with drug or 0.1% DMSO vehicle for 2 hours, followed by EGF (10 ng/mL) stimulation for 20 minutes. Cells were permeabilized and stained with rhodamine-phalloidin. Confocal images were taken on a Zeiss LSM 510 META confocal microscope. All quantification is based on three independent trials with 30 cells imaged in a battlement pattern and analyzed using Slidebook 5.5 software. Mean lengths or numbers of filopodia are plotted ±SEM. Statistically significant differences are indicated: *, P < 0.05; **, P < 0.01; ***, P < 0.001.
increased prevalence of R-ketorolac in vivo (12, 27, 28). Taken together, our identification of R-ketorolac as a GTPase inhibitor helps to explain the significant benefits of racemic ketorolac in human breast and ovarian cancer patient survival, and why other NSAIDs that preferentially target COX have not yielded similar benefit (6, 12, 32).

Ketorolac is an FDA-approved drug for human use and is in active clinical use as the racemic mix. Therefore, R-ketorolac has significant potential for rapid repurposing. Implementation of R-ketorolac in human clinical trials would offer the first opportunity to directly test the predicted benefit of a Cdc42- and Rac1-selective inhibitor for cancer patients. Such an application could circumvent current renal and hematologic toxicities that limit racemic ketorolac use to a maximum of 5 days. Analyses of Rac1 inhibition in cancer cell lines and animal models with NSC23766 treatment suggest benefit for inhibiting metastasis and angiogenesis (53). In addition, Rac1 inhibition may mitigate trastuzumab resistance in breast cancer cell lines, thus suggesting that the availability of a...
clinically accessible selective Cdc42 and Rac1 inhibitors could offer new paradigms for combinatorial therapies (53). We envision that the use of R-ketorolac in the perioperative window and thereafter presents a unique opportunity to block tumor reseeding and spread, as well as angiogenesis, which may enhance the efficacy of combined chemotherapies or targeted therapies.

Figure 6. R-ketorolac inhibits invadopodia formation and gelatin degradation in SKOV3ip and primary human ovarian cancer cells. A, colocalization of gelatin degradation, actin, and Tks5 in SKOV3ip cells. Insets are magnified images of the boxed regions. Arrowheads denote points of invadopodia formation that are coincident with gelatin degradation. B, representative confocal images of gelatin degradation for each treatment group in SKOV3ip cells are shown. Bottom panels are magnified images of the boxed regions. Arrowheads denote the gelatin degradation sites. C, representative confocal images of gelatin degradation for each treatment group in primary ovarian cancer cells are shown. Bottom panels are magnified images of the boxed regions. Arrowheads denote the gelatin degradation sites. D, quantification of the gelatin degradation area in SKOV3ip cells. E, quantification of the gelatin degradation area in primary ovarian cancer cells. Because of the variability of the extent of gelatin degradation observed with primary human ovarian cancer cells, z-scores are plotted. For all experiments, SKOV3ip cells or primary ovarian cancer cells were seeded on Cy3-gelatin–labeled coverslips for 24 hours in the presence of different drugs, including two enantiomers of ketorolac, and Cdc42- and Rac1-specific inhibitors (CID2950007 and NSC23766, respectively) as positive controls. DMSO (0.1%) served as the vehicle control treatment. All quantification is based on three independent trials with 15 representative fields counted for each treatment. Statistically significant differences are indicated: *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Disclosure of Potential Conflicts of Interest

L.A. Sklar has ownership interest in STC.unm GTPase patent. L.G. Hudson has ownership interest in a patent (allowance pending). A. Wandinger-Ness has ownership interest in a pending US patent. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions

Conception and design: Y. Guo, C.Y. Muller, L.A. Sklar, L.G. Hudson, A. Wandinger-Ness


Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Y. Guo, S.R. Kenney, C.Y. Muller, S. Adams, T. Rutledge, R. Prekeris, L.G. Hudson, A. Wandinger-Ness

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Y. Guo, S.R. Kenney, C. Murray-Krezan, L.G. Hudson, A. Wandinger-Ness

Writing, review, and/or revision of the manuscript: Y. Guo, S.R. Kenney, C.Y. Muller, S. Adams, T. Rutledge, C. Murray-Krezan, L.A. Sklar, L.G. Hudson, A. Wandinger-Ness

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): Y. Guo, E. Romero

Study supervision: L.G. Hudson, A. Wandinger-Ness

Grant Support

This work was supported by grants NCI R21 CA170375, DOD OC110514 W81XWH-11-OCCR-TEA, UNM Science and Technology Corporation Gap Fund (to A. Wandinger-Ness and L.G. Hudson), Core Facility support (Flow Cytometry Shared Resource, Fluorescence Microscopy Shared Resource, Clinical Trials Office) from the University of New Mexico Cancer Research and Treatment Center (F30 CA116100; to C. Willman). Focus Interactive Group grants from LIMN Cancer Center (09901M, 0990018 to A. Wandinger-Ness and L.G. Hudson). MH074425 and MH088469 (to L.A. Sklar). NCI R25CA153825 (predoctoral fellowship) and the George D. Montoya Scholarship (to Y. Guo), and INBRE NCCR 5P20RR016480 (predoctoral fellowship to S.R. Kenney).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 26, 2015; revised July 1, 2015; accepted July 6, 2015; published OnlineFirst July 23, 2015.

References


R-Ketorolac Targets GTPases and Ovarian Cancer Cell Invasion

S650–60.
is associated with improved epithelial ovarian cancer survival. Gynecol Oncol
31. Reyners AK, de Munck L, Erdkamp FL, Smit WM, Hoekman K, Lalisang RI,
et al. A randomized phase II study investigating the addition of the specific
COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line che-
motherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or
32. Forger P, Berliere M, van Maanen A, Duhoux FP, Machiels JP, Coulie PG,
et al. Perioperative ketorolac in high risk breast cancer patients. Rationale,
feasibility and methodology of a prospective randomized placebo-con-
Flow cytometry for real-time measurement of guanine nucleotide binding
regulates trafficking of Mmp2 and Mmp9 during invadopodia formation
35. Muller C. A pilot trial to study the availability and effect of post-OP IV
ketorolac on ovarian, fallopian tube or primary peritoneal cancer, cells
retrieved from the peritoneal cavity [cited 2015 May 18]. Available from:
https://clinicaltrials.gov/ct2/show/NCT01670799?
terms=ketorolac
+and+ovarian+cancer&rank
60.
36. Shepherd TG, Theriault BL, Campbell EJ, Nachigal MW. Primary culture of
ovarian surface epithelial cells and ascites-derived ovarian cancer cells from
competitive nucleotide binding inhibitor: in vitro characterization of Rab7
Rapid parallel flow cytometry assays of active GTPases using effector beads.
Overexpression of epithelial cell adhesion molecule in primary, metastatic,
and recurrent/chemotherapy-resistant epithelial ovarian cancer: implica-
tions for epithelial cell adhesion molecule-specific immunotherapy. Int J
41. Taylor DD, Gerecitaylor C, Parker LP. Patient-derived tumor-reactive
antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol
42. Zhao ZS, Manser E. PAK family kinases: physiological roles and regulation.
43. Dummler B, Ohshiro K, Kumar R, Field J. Pak protein kinases and their role
44. Bokoch GM, Reilly AM, Daniels RH, King CC, Olivera A, Spiegel S, et al. A
GTPase-independent mechanism of p21-activated kinase activation. Reg-
ulation by sphingosine and other biologically active lipids. J Biol Chem
1998;273:8137–44.
45. Diaz-Munoz MD, Osma-Garcia IC, Iniguez MA, Fresno M. Cyclooxygen-
ase-2 deficiency in macrophages leads to defective p110gamma PI3K
signaling and impairs cell adhesion and migration. J Immunol 2013;191:
395–406.
47. Matilha FK, Lappalainen P. Filopodia: molecular architecture and cellular
48. Courtenidge SA. Cell migration and invasion in human disease: the Tks
by DOCK exchange factors is mediated by a nucleotide sensor. Science
50. Duggan KC, Walters MJ, Muser J, Harp IM, Kiefer JR, Oates JA,
et al. Molecular basis for cyclooxygenase inhibition by the non-
34950–9.
et al. Do intraoperative analgesics influence breast cancer recurrence after
52. Dormond O, Foletti A, Paroz C, Ruegg C. NSAIDs inhibit alpha V beta 3
integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading,
53. Bid HK, Roberts RD, Manchanda PK, Houghton PJ. RAC1: an emerging
therapeutic option for targeting cancer angiogenesis and metastasis. Mol
Molecular Cancer Therapeutics

R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis

Yuna Guo, S. Ray Kenney, Carolyn Y. Muller, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-15-0419

Supplementary Material
Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2015/07/23/1535-7163.MCT-15-0419.DC1

Cited articles
This article cites 48 articles, 16 of which you can access for free at:
http://mct.aacrjournals.org/content/14/10/2215.full.html#ref-list-1

Citing articles
This article has been cited by 1 HighWire-hosted articles. Access the articles at:
/content/14/10/2215.full.html#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.